Anuh Pharma Limited (ANUHPHR.NS) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+12.6%

₹92.48

vs ₹82.11 price

Levered DCF

₹105.24

After debt service

Piotroski score

—

Altman Z-score

—

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
P/E	16.37×	16.29×	18.6×	30.87×	36.53×
P/B	1.91×	2.36×	3.83×	4.63×	5.22×
P/S	0.87×	1.17×	1.73×	2.12×	2.29×
EV / EBITDA	10.04×	10.83×	12.75×	19.44×	21.47×
Gross margin	17.4%	24.5%	24.8%	23.9%	22.4%
Operating margin	6.5%	8.6%	10.5%	8.4%	7.6%
Net margin	5.3%	7.2%	9.3%	6.9%	6.3%
Current ratio	2.22×	2.11×	2.22×	1.91×	1.98×
Debt / equity	0×	0.03×	0.01×	0×	0.02×
Interest coverage	106.58×	91.78×	191.36×	203.52×	38.72×
Dividend yield	2.2%	1.6%	0.9%	0.8%	0.7%
Payout ratio	36.5%	26.4%	16.7%	24.2%	24.7%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Return on equity	11.7%	14.5%	20.6%	15.0%	14.3%
Return on invested capital	10.8%	13.0%	17.6%	13.9%	13.2%
Return on assets	7.4%	9.3%	13.5%	8.9%	8.8%
Free cash flow yield	-1.6%	2.2%	0.7%	4.7%	2.4%
Earnings yield	6.1%	6.1%	5.4%	3.2%	2.7%
Enterprise value	₹6.6B	₹7.6B	₹11.1B	₹11.2B	₹11.2B
Net debt / EBITDA	-0.12×	-0.12×	-0.05×	-0.02×	0.01×
Cash conversion cycle (days)	90	59	59	46	63